img

Get In Touch

img

NIFTY 10192.95 img -47.20

SENSEX 33053.04 img -174.95

GOLD 28411.00

SILVER 36398.00

1 USD / INR 64.44

Attention Investors! "Prevent Unauthorised Transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of Investors."           Attention Investors! "Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from NSDL/CDSL on the same day. Issued in the interest of investors."           "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."           "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."           "As per SEBI guidelines, old DIS cannot be accepted for execution of instruction with effect from 07-01-2016. Kindly submit requisition slip / letter for issuance of new DIS booklet at our corporate office address to avoid rejection of your instruction(s) on or after 07-01-2016.”            "In accordance with the Union Budget 2017-18 announcement, SEBI has advised to link Aadhar with individual demat accounts. Kindly submit details of Aadhar number along with copy of Aadhar Card.”          

Market News

  • 12

    Oct
    2017

    Cadila Healthcare recovers after getting USFDA nod for drug

    The announcement was made during market hours today, 12 October 2017.

    Meanwhile, the S&P BSE Sensex was up 242.19 points, or 0.75% to 32,071.80.

    On the BSE, 42,411 shares were traded in the counter so far, compared with average daily volumes of 1.1 lakh shares in the past one quarter. The stock had hit a high of Rs 503 and a low of Rs 490.40 so far during the day. The stock had hit a record high of Rs 558 on 12 June 2017. The stock had hit a 52-week low of Rs 329.95 on 26 December 2016.

    The stock had dropped 1.87% in four sessions to settle at Rs 491.35 yesterday, 11 October 2017, from a close of Rs 500.75 on 5 October 2017.

    The stock had outperformed the market over the past one month till 11 October 2017, gaining 2.95% compared with the Sensex`s 0.15% fall. The stock had, however, underperformed the market over the past one quarter, dropping 5.05% as against the Sensex`s 0.27% rise. The scrip had, however, outperformed the market over the past one year, advancing 26.34% as against the Sensex`s 13.36% rise.

    The large-cap company has equity capital of Rs 102.37 crore. Face value per share is Re 1.

    Cadila Healthcare said that the drug is used to treat major depression and will be manufactured at the group`s formulations manufacturing facility at Moraiya, Ahmedabad, Gujarat.

    Cadila Healthcare`s consolidated net profit fell 65.3% to Rs 138.40 crore on 3.6% fall in net sales to Rs 2135.70 crore in Q1 June 2017 over Q1 June 2016.

    Cadila Healthcare is a global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

    Powered by Capital Market - Live News